icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025
Back grey_arrow_rt.gif
 
 
 
EFFECT OF 48-WEEK BULEVIRTIDE THERAPY ON NON-INVASIVE MARKERS OF LIVER FIBROSIS IN PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B/D
 
 
 
AASLD 2025 Nov 7-11 Wash DC
 
I. Mani1, E.Nasika1, A. Pelekanos1, V. Sevastianos2, V. Papadimitropoulos1, N. Papadopoulos1, H. Kranidioti1, A. Alexopoulou1, I. Koskinas1, G. Kontos1, M.Deutsch1, E. Hadziyannis1, and S.Manolakopoulos1
 
1. Liver-GI Unit, 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio", Medical School of National and Kapodistrian University of Athens 2. General Hospital of Athens "Evangelismos

1117251

1117252

1117253

1117254

1117255

1117256

1117257